{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:11:54Z","timestamp":1793711514834,"version":"4.6.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274018"],"award-info":[{"award-number":["82274018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The phosphatidylinositol 3-kinase (PI3K) signalling pathway regulates cell survival, proliferation, migration, metabolism and other vital cellular life processes. In addition, activation of the PI3K signalling pathway is important for cancer development. As a result, a variety of PI3K inhibitors have been clinically developed to treat malignancies. Although several PI3K inhibitors have received approval from the Food and Drug Administration (FDA) for significant antitumour activity, frequent and severe adverse effects have greatly limited their clinical application. These toxicities are mostly on-target and immune-mediated; nevertheless, the underlying mechanisms are still unclear. Current management usually involves intervention through symptomatic treatment, with discontinuation if toxicity persists. Therefore, it is necessary to comprehensively understand these adverse events and ensure the clinical safety application of PI3K inhibitors by establishing the most effective management guidelines, appropriate intermittent dosing regimens and new combination administration. Here, the focus is on the development of PI3K inhibitors in cancer therapy, with particular emphasis on isoform-specific PI3K inhibitors. The most common adverse effects of PI3K inhibitors are also covered, as well as potential mechanisms and management approaches.<\/jats:p>","DOI":"10.1007\/s00204-023-03440-4","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T11:37:39Z","timestamp":1676115459000},"page":"635-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Development and safety of PI3K inhibitors in cancer"],"prefix":"10.1007","volume":"97","author":[{"given":"Miaomiao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaojun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-7212","authenticated-orcid":false,"given":"Hao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,11]]},"reference":[{"key":"3440_CR1","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.3389\/fimmu.2018.02574","volume":"9","author":"E Aksoy","year":"2018","unstructured":"Aksoy E, Saveanu L, Manoury B (2018) The isoform selective roles of pi3ks in dendritic cell biology and function. Front Immunol 9:2574. https:\/\/doi.org\/10.3389\/fimmu.2018.02574","journal-title":"Front Immunol"},{"issue":"8","key":"3440_CR2","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1093\/annonc\/mds115","volume":"23","author":"L Albiges","year":"2012","unstructured":"Albiges L, Chamming\u2019s F, Duclos B et al (2012) Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 23(8):1943\u20131953. https:\/\/doi.org\/10.1093\/annonc\/mds115","journal-title":"Ann Oncol"},{"key":"3440_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050953","author":"K Anderson","year":"2021","unstructured":"Anderson K, Ryan N, Alkhimovitch A, Siddiqui A, Oghumu S (2021) Inhibition of PI3K Isoform p110gamma increases both anti-tumor and immunosuppressive responses to aggressive murine head and neck squamous cell carcinoma with low immunogenicity. Cancers. https:\/\/doi.org\/10.3390\/cancers13050953","journal-title":"Cancers"},{"issue":"20","key":"3440_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 380(20):1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"issue":"2","key":"3440_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","volume":"32","author":"F Andre","year":"2021","unstructured":"Andre F, Ciruelos EM, Juric D et al (2021) Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 32(2):208\u2013217. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.011","journal-title":"Ann Oncol"},{"key":"3440_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2019.02.002","volume":"59","author":"R Arafeh","year":"2019","unstructured":"Arafeh R, Samuels Y (2019) PIK3CA in cancer: The past 30 years. Semin Cancer Biol 59:36\u201349. https:\/\/doi.org\/10.1016\/j.semcancer.2019.02.002","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"3440_CR7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/s41467-019-09514-1","volume":"10","author":"C Araiz","year":"2019","unstructured":"Araiz C, Yan A, Bettedi L et al (2019) Enhanced beta-adrenergic signalling underlies an age-dependent beneficial metabolic effect of PI3K p110alpha inactivation in adipose tissue. Nat Commun 10(1):1546. https:\/\/doi.org\/10.1038\/s41467-019-09514-1","journal-title":"Nat Commun"},{"issue":"2","key":"3440_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1021\/jm501629p","volume":"58","author":"B Barlaam","year":"2015","unstructured":"Barlaam B, Cosulich S, Degorce S et al (2015) Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N, N-dimethyl-2-morpholino-4-oxo-4H-chrom ene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kbeta and PI3Kdelta for the treatment of PTEN-deficient cancers. J Med Chem 58(2):943\u2013962. https:\/\/doi.org\/10.1021\/jm501629p","journal-title":"J Med Chem"},{"issue":"20","key":"3440_CR9","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","volume":"127","author":"PM Barr","year":"2016","unstructured":"Barr PM, Saylors GB, Spurgeon SE et al (2016) Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood 127(20):2411\u20132415. https:\/\/doi.org\/10.1182\/blood-2015-12-683516","journal-title":"Blood"},{"key":"3440_CR10","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.2147\/OTT.S102573","volume":"9","author":"JC Barrientos","year":"2016","unstructured":"Barrientos JC (2016) Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. Onco Targets Ther 9:2945\u20132953. https:\/\/doi.org\/10.2147\/OTT.S102573","journal-title":"Onco Targets Ther"},{"issue":"7","key":"3440_CR11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","volume":"18","author":"J Baselga","year":"2017","unstructured":"Baselga J, Im SA, Iwata H et al (2017) Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(7):904\u2013916. https:\/\/doi.org\/10.1016\/S1470-2045(17)30376-5","journal-title":"Lancet Oncol"},{"issue":"8","key":"3440_CR12","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-21-3045","volume":"28","author":"F Batalini","year":"2022","unstructured":"Batalini F, Xiong N, Tayob N et al (2022) Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Clin Cancer Res 28(8):1493\u20131499. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3045","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3440_CR13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","volume":"20","author":"B Bilanges","year":"2019","unstructured":"Bilanges B, Posor Y, Vanhaesebroeck B (2019) PI3K isoforms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol 20(9):515\u2013534. https:\/\/doi.org\/10.1038\/s41580-019-0129-z","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"17","key":"3440_CR14","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA (2018) Duvelisib: First Global Approval. Drugs 78(17):1847\u20131853. https:\/\/doi.org\/10.1007\/s40265-018-1013-4","journal-title":"Drugs"},{"issue":"12","key":"3440_CR15","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1007\/s00262-021-02988-3","volume":"70","author":"C Braun","year":"2021","unstructured":"Braun C, Schlaweck S, Daecke SN, Brossart P, Heine A (2021) The PI3Kdelta inhibitor idelalisib impairs the function of human dendritic cells. Cancer Immunol Immunother 70(12):3693\u20133700. https:\/\/doi.org\/10.1007\/s00262-021-02988-3","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3440_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.clml.2018.11.021","volume":"19","author":"BD Cheson","year":"2019","unstructured":"Cheson BD, O\u2019Brien S, Ewer MS et al (2019) Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas. Clin Lymphoma Myeloma Leuk 19(3):135\u2013141. https:\/\/doi.org\/10.1016\/j.clml.2018.11.021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"3440_CR17","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-21-3087","volume":"28","author":"AD Choudhury","year":"2022","unstructured":"Choudhury AD, Higano CS, de Bono JS et al (2022) A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kbeta\/delta, in Patients with Advanced Solid Tumors. Clin Cancer Res 28(11):2257\u20132269","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3440_CR18","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"SE Coutre","year":"2015","unstructured":"Coutre SE, Barrientos JC, Brown JR et al (2015) Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 56(10):2779\u20132786. https:\/\/doi.org\/10.3109\/10428194.2015.1022770","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3440_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/hon.2540","volume":"37","author":"A Cuneo","year":"2019","unstructured":"Cuneo A, Barosi G, Danesi R et al (2019) Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper. Hematol Oncol 37(1):3\u201314. https:\/\/doi.org\/10.1002\/hon.2540","journal-title":"Hematol Oncol"},{"issue":"2","key":"3440_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40264-018-0778-4","volume":"42","author":"G Curigliano","year":"2019","unstructured":"Curigliano G, Shah RR (2019) Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. Drug Saf 42(2):247\u2013262. https:\/\/doi.org\/10.1007\/s40264-018-0778-4","journal-title":"Drug Saf"},{"issue":"4","key":"3440_CR21","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41375-020-01010-6","volume":"35","author":"MS Davids","year":"2021","unstructured":"Davids MS, Fisher DC, Tyekucheva S et al (2021a) A phase 1b\/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia 35(4):1064\u20131072. https:\/\/doi.org\/10.1038\/s41375-020-01010-6","journal-title":"Leukemia"},{"issue":"23","key":"3440_CR22","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1182\/bloodadvances.2021005132","volume":"5","author":"MS Davids","year":"2021","unstructured":"Davids MS, O\u2019Connor OA, Jurczak W et al (2021b) Integrated safety analysis of umbralisib, a dual PI3Kdelta\/CK1epsilon inhibitor, in relapsed\/refractory lymphoid malignancies. Blood Adv 5(23):5332\u20135343. https:\/\/doi.org\/10.1182\/bloodadvances.2021005132","journal-title":"Blood Adv"},{"issue":"7629","key":"3440_CR23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau O, Rausch M, Winkler D et al (2016) Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539(7629):443\u2013447. https:\/\/doi.org\/10.1038\/nature20554","journal-title":"Nature"},{"issue":"2","key":"3440_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.bbcan.2019.03.003","volume":"1871","author":"MC De Santis","year":"2019","unstructured":"De Santis MC, Gulluni F, Campa CC, Martini M, Hirsch E (2019) Targeting PI3K signaling in cancer: Challenges and advances. Biochim Biophys Acta Rev Cancer 1871(2):361\u2013366. https:\/\/doi.org\/10.1016\/j.bbcan.2019.03.003","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"8","key":"3440_CR25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/ced.13608","volume":"43","author":"AK Dewan","year":"2018","unstructured":"Dewan AK, Sowerby L, Jadeja S et al (2018) Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition. Clin Exp Dermatol 43(8):890\u2013894. https:\/\/doi.org\/10.1111\/ced.13608","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"3440_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40265-021-01504-2","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S, Keam SJ (2021) Umbralisib: First Approval. Drugs 81(7):857\u2013866. https:\/\/doi.org\/10.1007\/s40265-021-01504-2","journal-title":"Drugs"},{"issue":"1","key":"3440_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","volume":"19","author":"A Di Leo","year":"2018","unstructured":"Di Leo A, Johnston S, Lee KS et al (2018) Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19(1):87\u2013100. https:\/\/doi.org\/10.1016\/S1470-2045(17)30688-5","journal-title":"Lancet Oncol"},{"issue":"9","key":"3440_CR28","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Morschhauser F, Bouabdallah K et al (2017a) Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol 28(9):2169\u20132178. https:\/\/doi.org\/10.1093\/annonc\/mdx289","journal-title":"Ann Oncol"},{"issue":"35","key":"3440_CR29","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L et al (2017b) Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 35(35):3898\u20133905. https:\/\/doi.org\/10.1200\/JCO.2017.75.4648","journal-title":"J Clin Oncol"},{"issue":"4","key":"3440_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ajh.25711","volume":"95","author":"M Dreyling","year":"2020","unstructured":"Dreyling M, Santoro A, Mollica L et al (2020) Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol 95(4):362\u2013371. https:\/\/doi.org\/10.1002\/ajh.25711","journal-title":"Am J Hematol"},{"issue":"7911","key":"3440_CR31","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","volume":"605","author":"S Eschweiler","year":"2022","unstructured":"Eschweiler S, Ramirez-Suastegui C, Li Y et al (2022) Intermittent PI3Kdelta inhibition sustains anti-tumour immunity and curbs irAEs. Nature 605(7911):741\u2013746. https:\/\/doi.org\/10.1038\/s41586-022-04685-2","journal-title":"Nature"},{"issue":"9","key":"3440_CR32","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jamaoncol.2019.0034","volume":"5","author":"A Esposito","year":"2019","unstructured":"Esposito A, Viale G, Curigliano G (2019) Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review. JAMA Oncol 5(9):1347\u20131354. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0034","journal-title":"JAMA Oncol"},{"issue":"23","key":"3440_CR33","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M et al (2018) The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood 132(23):2446\u20132455. https:\/\/doi.org\/10.1182\/blood-2018-05-850461","journal-title":"Blood"},{"issue":"12","key":"3440_CR34","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/ajh.25634","volume":"94","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Cherry MA, Maris MB, Matous JV, Berdeja JG, Patel M (2019a) Combination trial of duvelisib (IPI-145) with rituximab or bendamustine\/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. Am J Hematol 94(12):1325\u20131334. https:\/\/doi.org\/10.1002\/ajh.25634","journal-title":"Am J Hematol"},{"issue":"11","key":"3440_CR35","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/JCO.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM et al (2019b) DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol 37(11):912\u2013922. https:\/\/doi.org\/10.1200\/JCO.18.00915","journal-title":"J Clin Oncol"},{"issue":"15","key":"3440_CR36","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/JCO.20.03433","volume":"39","author":"NH Fowler","year":"2021","unstructured":"Fowler NH, Samaniego F, Jurczak W et al (2021) Umbralisib, a Dual PI3Kdelta\/CK1epsilon Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 39(15):1609\u20131618. https:\/\/doi.org\/10.1200\/JCO.20.03433","journal-title":"J Clin Oncol"},{"issue":"4","key":"3440_CR37","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT (2017) The PI3K Pathway in Human Disease. Cell 170(4):605\u2013635. https:\/\/doi.org\/10.1016\/j.cell.2017.07.029","journal-title":"Cell"},{"issue":"4","key":"3440_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0249-8","volume":"51","author":"T Fujikawa","year":"2019","unstructured":"Fujikawa T, Choi YH, Yang DJ et al (2019) P110beta in the ventromedial hypothalamus regulates glucose and energy metabolism. Exp Mol Med 51(4):1\u20139. https:\/\/doi.org\/10.1038\/s12276-019-0249-8","journal-title":"Exp Mol Med"},{"issue":"11","key":"3440_CR39","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997\u20131007. https:\/\/doi.org\/10.1056\/NEJMoa1315226","journal-title":"N Engl J Med"},{"issue":"11","key":"3440_CR40","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1634\/theoncologist.2015-0519","volume":"21","author":"JW Goldman","year":"2016","unstructured":"Goldman JW, Mendenhall MA, Rettinger SR (2016) Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management. Oncologist 21(11):1326\u20131336. https:\/\/doi.org\/10.1634\/theoncologist.2015-0519","journal-title":"Oncologist"},{"issue":"11","key":"3440_CR41","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S et al (2014) PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008\u20131018. https:\/\/doi.org\/10.1056\/NEJMoa1314583","journal-title":"N Engl J Med"},{"issue":"6","key":"3440_CR42","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41419-018-0717-4","volume":"9","author":"E Goulielmaki","year":"2018","unstructured":"Goulielmaki E, Bermudez-Brito M, Andreou M et al (2018) Pharmacological inactivation of the PI3K p110delta prevents breast tumour progression by targeting cancer cells and macrophages. Cell Death Dis 9(6):678. https:\/\/doi.org\/10.1038\/s41419-018-0717-4","journal-title":"Cell Death Dis"},{"issue":"1","key":"3440_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1158\/1535-7163.MCT-14-0406","volume":"14","author":"U Hancox","year":"2015","unstructured":"Hancox U, Cosulich S, Hanson L et al (2015) Inhibition of PI3Kbeta signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. Mol Cancer Ther 14(1):48\u201358. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0406","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"3440_CR44","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1158\/2159-8290.CD-18-1175","volume":"9","author":"AB Hanker","year":"2019","unstructured":"Hanker AB, Kaklamani V, Arteaga CL (2019) Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. Cancer Discov 9(4):482\u2013491. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1175","journal-title":"Cancer Discov"},{"issue":"4","key":"3440_CR45","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1183\/13993003.01670-2015","volume":"47","author":"E Haustraete","year":"2016","unstructured":"Haustraete E, Obert J, Diab S et al (2016) Idelalisib-related pneumonitis. Eur Respir J 47(4):1280\u20131283. https:\/\/doi.org\/10.1183\/13993003.01670-2015","journal-title":"Eur Respir J"},{"issue":"1","key":"3440_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6(1):425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","journal-title":"Signal Transduct Target Ther"},{"issue":"7719","key":"3440_CR47","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","volume":"560","author":"BD Hopkins","year":"2018","unstructured":"Hopkins BD, Pauli C, Du X et al (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560(7719):499\u2013503. https:\/\/doi.org\/10.1038\/s41586-018-0343-4","journal-title":"Nature"},{"issue":"8","key":"3440_CR48","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Koch R, Porcu P et al (2018) Activity of the PI3K-delta, gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 131(8):888\u2013898. https:\/\/doi.org\/10.1182\/blood-2017-08-802470","journal-title":"Blood"},{"issue":"5","key":"3440_CR49","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1111\/jdv.14700","volume":"32","author":"L Huilaja","year":"2018","unstructured":"Huilaja L, Lindgren O, Soronen M, Siitonen T, Tasanen K (2018) A slowly developed severe cutaneous adverse reaction to idelalisib. J Eur Acad Dermatol Venereol 32(5):e192\u2013e193. https:\/\/doi.org\/10.1111\/jdv.14700","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"24","key":"3440_CR50","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/blood.2020010187","volume":"137","author":"A Iannello","year":"2021","unstructured":"Iannello A, Vitale N, Coma S et al (2021) Synergistic efficacy of the dual PI3K-delta\/gamma inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood 137(24):3378\u20133389. https:\/\/doi.org\/10.1182\/blood.2020010187","journal-title":"Blood"},{"issue":"5","key":"3440_CR51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku F, Yap TA, Meric-Bernstam F (2018) Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol 15(5):273\u2013291. https:\/\/doi.org\/10.1038\/nrclinonc.2018.28","journal-title":"Nat Rev Clin Oncol"},{"key":"3440_CR52","doi-asserted-by":"publisher","first-page":"119239","DOI":"10.1016\/j.ijpharm.2020.119239","volume":"581","author":"M Jiang","year":"2020","unstructured":"Jiang M, He K, Qiu T et al (2020) Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment. Int J Pharm 581:119239","journal-title":"Int J Pharm"},{"issue":"13","key":"3440_CR53","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","volume":"36","author":"D Juric","year":"2018","unstructured":"Juric D, Rodon J, Tabernero J et al (2018) Phosphatidylinositol 3-Kinase alpha-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol 36(13):1291\u20131299. https:\/\/doi.org\/10.1200\/JCO.2017.72.7107","journal-title":"J Clin Oncol"},{"issue":"2","key":"3440_CR54","doi-asserted-by":"publisher","first-page":"e184475","DOI":"10.1001\/jamaoncol.2018.4475","volume":"5","author":"D Juric","year":"2019","unstructured":"Juric D, Janku F, Rodon J et al (2019) Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol 5(2):e184475","journal-title":"JAMA Oncol"},{"issue":"6","key":"3440_CR55","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41571-021-00512-1","volume":"18","author":"D Killock","year":"2021","unstructured":"Killock D (2021) Copanlisib safe and active in combination. Nat Rev Clin Oncol 18(6):322. https:\/\/doi.org\/10.1038\/s41571-021-00512-1","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"3440_CR56","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","volume":"26","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Brown JR (2017) PI3Kdelta-selective and PI3Kalpha\/delta-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 26(11):1267\u20131279. https:\/\/doi.org\/10.1080\/13543784.2017.1384815","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"3440_CR57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson BL, Kasar SN, Matos TR et al (2016) Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128(2):195\u2013203. https:\/\/doi.org\/10.1182\/blood-2016-03-707133","journal-title":"Blood"},{"issue":"7","key":"3440_CR58","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/bloodadvances.2018030221","volume":"3","author":"BL Lampson","year":"2019","unstructured":"Lampson BL, Kim HT, Davids MS et al (2019) Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv 3(7):1167\u20131174. https:\/\/doi.org\/10.1182\/bloodadvances.2018030221","journal-title":"Blood Adv"},{"issue":"8","key":"3440_CR59","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1038\/s41375-020-0743-y","volume":"34","author":"G Lenz","year":"2020","unstructured":"Lenz G, Hawkes E, Verhoef G et al (2020) Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia 34(8):2184\u20132197. https:\/\/doi.org\/10.1038\/s41375-020-0743-y","journal-title":"Leukemia"},{"issue":"7","key":"3440_CR60","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","volume":"138","author":"M Li","year":"2018","unstructured":"Li M, Sala V, De Santis MC et al (2018) Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation 138(7):696\u2013711. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030352","journal-title":"Circulation"},{"issue":"1","key":"3440_CR61","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13287-019-1366-y","volume":"10","author":"JY Li","year":"2019","unstructured":"Li JY, Ren KK, Zhang WJ et al (2019) Human amniotic mesenchymal stem cells and their paracrine factors promote wound healing by inhibiting heat stress-induced skin cell apoptosis and enhancing their proliferation through activating PI3K\/AKT signaling pathway. Stem Cell Res Ther 10(1):247. https:\/\/doi.org\/10.1186\/s13287-019-1366-y","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"3440_CR62","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejvs.2020.03.042","volume":"60","author":"R Liu","year":"2020","unstructured":"Liu R, Huang J, Ge Y et al (2020) Inhibition of Phosphatidylinositol 3-Kinase gamma by IPI-549 Attenuates Abdominal Aortic Aneurysm Formation in Mice. Eur J Vasc Endovasc Surg 60(2):254\u2013263. https:\/\/doi.org\/10.1016\/j.ejvs.2020.03.042","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"12","key":"3440_CR63","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1097\/PAS.0000000000000525","volume":"39","author":"CY Louie","year":"2015","unstructured":"Louie CY, DiMaio MA, Matsukuma KE, Coutre SE, Berry GJ, Longacre TA (2015) Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides. Am J Surg Pathol 39(12):1653\u20131660. https:\/\/doi.org\/10.1097\/PAS.0000000000000525","journal-title":"Am J Surg Pathol"},{"issue":"24","key":"3440_CR64","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.1158\/1078-0432.CCR-17-0676","volume":"23","author":"JT Lynch","year":"2017","unstructured":"Lynch JT, Polanska UM, Delpuech O et al (2017) Inhibiting PI3Kbeta with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clin Cancer Res 23(24):7584\u20137595. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0676","journal-title":"Clin Cancer Res"},{"issue":"11","key":"3440_CR65","doi-asserted-by":"publisher","first-page":"e1009876","DOI":"10.1371\/journal.pgen.1009876","volume":"17","author":"RR Madsen","year":"2021","unstructured":"Madsen RR, Erickson EC, Rueda OM et al (2021) Positive correlation between transcriptomic stemness and PI3K\/AKT\/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype. PLoS Genet 17(11):e1009876","journal-title":"PLoS Genet"},{"issue":"13","key":"3440_CR66","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1182\/bloodadvances.2020001800","volume":"4","author":"K Maharaj","year":"2020","unstructured":"Maharaj K, Powers JJ, Achille A et al (2020) The dual PI3Kdelta\/CK1epsilon inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv 4(13):3072\u20133084. https:\/\/doi.org\/10.1182\/bloodadvances.2020001800","journal-title":"Blood Adv"},{"issue":"2","key":"3440_CR67","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","volume":"11","author":"SM Maira","year":"2012","unstructured":"Maira SM, Pecchi S, Huang A et al (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 11(2):317\u2013328. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0474","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3440_CR68","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1038\/s41467-021-25341-9","volume":"12","author":"N Mao","year":"2021","unstructured":"Mao N, Zhang Z, Lee YS et al (2021) Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nat Commun 12(1):5053. https:\/\/doi.org\/10.1038\/s41467-021-25341-9","journal-title":"Nat Commun"},{"issue":"14","key":"3440_CR69","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham A (2014) Idelalisib: first global approval. Drugs 74(14):1701\u20131707. https:\/\/doi.org\/10.1007\/s40265-014-0285-6","journal-title":"Drugs"},{"issue":"18","key":"3440_CR70","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s40265-017-0838-6","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A (2017) Copanlisib: First Global Approval. Drugs 77(18):2057\u20132062. https:\/\/doi.org\/10.1007\/s40265-017-0838-6","journal-title":"Drugs"},{"issue":"11","key":"3440_CR71","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A (2019) Alpelisib: First Global Approval. Drugs 79(11):1249\u20131253. https:\/\/doi.org\/10.1007\/s40265-019-01161-6","journal-title":"Drugs"},{"issue":"6","key":"3440_CR72","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.eururo.2014.08.053","volume":"67","author":"RB Marques","year":"2015","unstructured":"Marques RB, Aghai A, de Ridder CMA et al (2015) High Efficacy of Combination Therapy Using PI3K\/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. Eur Urol 67(6):1177\u20131185. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.053","journal-title":"Eur Urol"},{"issue":"4","key":"3440_CR73","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/0008-5472.CAN-19-1633","volume":"80","author":"M Marques","year":"2020","unstructured":"Marques M, Tranchant R, Risa-Ebri B et al (2020) Combined MEK and PI3K\/p110beta Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer Res 80(4):843\u2013856. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1633","journal-title":"Cancer Res"},{"issue":"5","key":"3440_CR74","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","volume":"22","author":"MJ Matasar","year":"2021","unstructured":"Matasar MJ, Capra M, Ozcan M et al (2021) Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 22(5):678\u2013689. https:\/\/doi.org\/10.1016\/S1470-2045(21)00145-5","journal-title":"Lancet Oncol"},{"issue":"19","key":"3440_CR75","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","volume":"23","author":"J Mateo","year":"2017","unstructured":"Mateo J, Ganji G, Lemech C et al (2017) A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 23(19):5981\u20135992. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0725","journal-title":"Clin Cancer Res"},{"issue":"20","key":"3440_CR76","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1002\/cncr.33071","volume":"126","author":"V McPherson","year":"2020","unstructured":"McPherson V, Reardon B, Bhayankara A et al (2020) A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. Cancer 126(20):4532\u20134544. https:\/\/doi.org\/10.1002\/cncr.33071","journal-title":"Cancer"},{"key":"3440_CR77","unstructured":"Meeting of the oncologic drugs advisory committee (2022) U.S. Food and Drug Administration. https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/updated-information-april-21-22-2022-meeting-oncologic-drugs-advisory-committee-meeting-announcement. Accessed 21 April 2022."},{"key":"3440_CR78","doi-asserted-by":"publisher","first-page":"105900","DOI":"10.1016\/j.phrs.2021.105900","volume":"173","author":"D Meng","year":"2021","unstructured":"Meng D, He W, Zhang Y et al (2021) Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review). Pharmacol Res 173:105900","journal-title":"Pharmacol Res"},{"key":"3440_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/biom9030082","author":"MS Miller","year":"2019","unstructured":"Miller MS, Thompson PE, Gabelli SB (2019) Structural Determinants of Isoform Selectivity in PI3K Inhibitors. Biomolecules. https:\/\/doi.org\/10.3390\/biom9030082","journal-title":"Biomolecules"},{"key":"3440_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073464","author":"R Mishra","year":"2021","unstructured":"Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT (2021) PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22073464","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3440_CR81","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.cmet.2019.03.010","volume":"29","author":"A Molinaro","year":"2019","unstructured":"Molinaro A, Becattini B, Mazzoli A et al (2019) Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kalpha and PI3Kbeta Activities and Is Promoted by RAS. Cell Metab 29(6):1400-1409.e5. https:\/\/doi.org\/10.1016\/j.cmet.2019.03.010","journal-title":"Cell Metab"},{"issue":"1","key":"3440_CR82","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41598-018-37012-9","volume":"9","author":"SF Moore","year":"2019","unstructured":"Moore SF, Smith NR, Blair TA, Durrant TN, Hers I (2019) Critical roles for the phosphatidylinositide 3-kinase isoforms p110beta and p110gamma in thrombopoietin-mediated priming of platelet function. Sci Rep 9(1):1468. https:\/\/doi.org\/10.1038\/s41598-018-37012-9","journal-title":"Sci Rep"},{"issue":"7","key":"3440_CR83","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1038\/s41375-020-01108-x","volume":"35","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Dyer MJS, Walter HS et al (2021) Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. Leukemia 35(7):2108\u20132113. https:\/\/doi.org\/10.1038\/s41375-020-01108-x","journal-title":"Leukemia"},{"issue":"3","key":"3440_CR84","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11523-021-00802-9","volume":"16","author":"J Munoz","year":"2021","unstructured":"Munoz J, Follows GA, Nastoupil LJ (2021) Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. Target Oncol 16(3):295\u2013308. https:\/\/doi.org\/10.1007\/s11523-021-00802-9","journal-title":"Target Oncol"},{"issue":"2","key":"3440_CR85","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/2040620715625966","volume":"7","author":"KS Nair","year":"2016","unstructured":"Nair KS, Cheson B (2016) The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia. Ther Adv Hematol 7(2):69\u201384. https:\/\/doi.org\/10.1177\/2040620715625966","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"3440_CR86","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1158\/0008-5472.CAN-15-2201","volume":"76","author":"Y Nakanishi","year":"2016","unstructured":"Nakanishi Y, Walter K, Spoerke JM et al (2016) Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110beta. Cancer Res 76(5):1193\u20131203. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2201","journal-title":"Cancer Res"},{"issue":"2","key":"3440_CR87","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1016\/S2352-3026(18)30216-3","volume":"6","author":"LJ Nastoupil","year":"2019","unstructured":"Nastoupil LJ, Lunning MA, Vose JM et al (2019) Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol 6(2):e100\u2013e109. https:\/\/doi.org\/10.1016\/S2352-3026(18)30216-3","journal-title":"Lancet Haematol"},{"issue":"Suppl 10","key":"3440_CR88","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","volume":"30","author":"SE Nunnery","year":"2019","unstructured":"Nunnery SE, Mayer IA (2019) Management of toxicity to isoform alpha-specific PI3K inhibitors. Ann Oncol 30(Suppl 10):x21\u2013x26. https:\/\/doi.org\/10.1093\/annonc\/mdz440","journal-title":"Ann Oncol"},{"key":"3440_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/biom9090427","author":"B Nurnberg","year":"2019","unstructured":"Nurnberg B, Beer-Hammer S (2019) Function, regulation and biological roles of PI3Kgamma variants. Biomolecules. https:\/\/doi.org\/10.3390\/biom9090427","journal-title":"Biomolecules"},{"key":"3440_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17111858","author":"M Perrotta","year":"2016","unstructured":"Perrotta M, Lembo G, Carnevale D (2016) The multifaceted roles of pi3kgamma in hypertension, vascular biology, and inflammation. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms17111858","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3440_CR91","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/neuonc\/nox181","volume":"20","author":"KJ Pridham","year":"2018","unstructured":"Pridham KJ, Le L, Guo S et al (2018) PIK3CB\/p110beta is a selective survival factor for glioblastoma. Neuro Oncol 20(4):494\u2013505. https:\/\/doi.org\/10.1093\/neuonc\/nox181","journal-title":"Neuro Oncol"},{"key":"3440_CR92","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0964","author":"LE Roeker","year":"2022","unstructured":"Roeker LE, Feldman TA, Soumerai JD et al (2022) Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0964","journal-title":"Clin Cancer Res"},{"key":"3440_CR93","doi-asserted-by":"publisher","first-page":"608625","DOI":"10.3389\/fimmu.2021.608625","volume":"12","author":"L Rohrbacher","year":"2021","unstructured":"Rohrbacher L, Brauchle B, Ogrinc Wagner A, von Bergwelt-Baildon M, Bucklein VL, Subklewe M (2021) The PI3K partial differential-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression. Front Immunol 12:608625","journal-title":"Front Immunol"},{"key":"3440_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000672","author":"M Rosenthal","year":"2020","unstructured":"Rosenthal M, Clement PM, Campone M et al (2020) Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib\/II, open-label, multicentre, randomised study. ESMO Open. https:\/\/doi.org\/10.1136\/esmoopen-2020-000672","journal-title":"ESMO Open"},{"key":"3440_CR95","doi-asserted-by":"publisher","first-page":"105579","DOI":"10.1016\/j.phrs.2021.105579","volume":"168","author":"R Roskoski Jr","year":"2021","unstructured":"Roskoski R Jr (2021) Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacol Res 168:105579","journal-title":"Pharmacol Res"},{"issue":"8","key":"3440_CR96","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","volume":"31","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Andre F, Yamashita T et al (2020) Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 31(8):1001\u20131010. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.001","journal-title":"Ann Oncol"},{"issue":"4","key":"3440_CR97","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","volume":"22","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Lerebours F, Ciruelos E et al (2021) Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 22(4):489\u2013498. https:\/\/doi.org\/10.1016\/S1470-2045(21)00034-6","journal-title":"Lancet Oncol"},{"issue":"19","key":"3440_CR98","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.1158\/1078-0432.CCR-21-1115","volume":"27","author":"D Sarker","year":"2021","unstructured":"Sarker D, Dawson NA, Aparicio AM et al (2021) A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kbeta Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 27(19):5248\u20135257. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1115","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3440_CR99","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccell.2014.11.008","volume":"27","author":"S Schwartz","year":"2015","unstructured":"Schwartz S, Wongvipat J, Trigwell CB et al (2015) Feedback suppression of PI3Kalpha signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kbeta. Cancer Cell 27(1):109\u2013122. https:\/\/doi.org\/10.1016\/j.ccell.2014.11.008","journal-title":"Cancer Cell"},{"issue":"14","key":"3440_CR100","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-20-4879","volume":"27","author":"P Sharma","year":"2021","unstructured":"Sharma P, Abramson VG, O\u2019Dea A et al (2021) Clinical and Biomarker Results from Phase I\/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. Clin Cancer Res 27(14):3896\u20133904. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4879","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3440_CR101","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.18.01460","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Coutre SE, Furman RR et al (2019) Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol 37(16):1391\u20131402. https:\/\/doi.org\/10.1200\/JCO.18.01460","journal-title":"J Clin Oncol"},{"issue":"3","key":"3440_CR102","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","volume":"18","author":"D Soulieres","year":"2017","unstructured":"Soulieres D, Faivre S, Mesia R et al (2017) Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol 18(3):323\u2013335. https:\/\/doi.org\/10.1016\/S1470-2045(17)30064-5","journal-title":"Lancet Oncol"},{"issue":"1","key":"3440_CR103","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15(1):7\u201324. https:\/\/doi.org\/10.1038\/nrc3860","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3440_CR104","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/bloodadvances.2020003895","volume":"5","author":"C Tomowiak","year":"2021","unstructured":"Tomowiak C, Poulain S, Herbaux C et al (2021) Obinutuzumab and idelalisib in symptomatic patients with relapsed\/refractory Waldenstrom macroglobulinemia. Blood Adv 5(9):2438\u20132446. https:\/\/doi.org\/10.1182\/bloodadvances.2020003895","journal-title":"Blood Adv"},{"issue":"29","key":"3440_CR105","doi-asserted-by":"publisher","first-page":"14724","DOI":"10.1073\/pnas.1813012116","volume":"116","author":"C Torres","year":"2019","unstructured":"Torres C, Mancinelli G, Cordoba-Chacon J et al (2019) p110gamma deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity. Proc Natl Acad Sci U S A 116(29):14724\u201314733. https:\/\/doi.org\/10.1073\/pnas.1813012116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3440_CR106","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1053\/j.gastro.2010.07.008","volume":"139","author":"JK Uno","year":"2010","unstructured":"Uno JK, Rao KN, Matsuoka K et al (2010) Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110delta. Gastroenterology 139(5):1642\u20131653","journal-title":"Gastroenterology"},{"key":"3440_CR107","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ejca.2019.06.026","volume":"119","author":"PA van Dam","year":"2019","unstructured":"van Dam PA (2019) The use of buparlisib as a radiosentisiser: What about toxicity? Eur J Cancer 119:194\u2013195. https:\/\/doi.org\/10.1016\/j.ejca.2019.06.026","journal-title":"Eur J Cancer"},{"issue":"6","key":"3440_CR108","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1161\/ATVBAHA.114.304887","volume":"35","author":"M Vantler","year":"2015","unstructured":"Vantler M, Jesus J, Leppanen O et al (2015) Class IA Phosphatidylinositol 3-Kinase Isoform p110alpha Mediates Vascular Remodeling. Arterioscler Thromb Vasc Biol 35(6):1434\u20131444. https:\/\/doi.org\/10.1161\/ATVBAHA.114.304887","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3440_CR109","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.bbadis.2018.02.003","volume":"1864","author":"P Varshney","year":"2018","unstructured":"Varshney P, Saini N (2018) PI3K\/AKT\/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis. Biochim Biophys Acta Mol Basis Dis 1864:1795\u20131803","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"12","key":"3440_CR110","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","volume":"39","author":"AS Weidner","year":"2015","unstructured":"Weidner AS, Panarelli NC, Geyer JT et al (2015) Idelalisib-associated Colitis: Histologic Findings in 14 Patients. Am J Surg Pathol 39(12):1661\u20131667. https:\/\/doi.org\/10.1097\/PAS.0000000000000522","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"3440_CR111","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1200\/JCO.18.01207","volume":"37","author":"PY Wen","year":"2019","unstructured":"Wen PY, Touat M, Alexander BM et al (2019) Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm. Phase II Trial J Clin Oncol 37(9):741\u2013750. https:\/\/doi.org\/10.1200\/JCO.18.01207","journal-title":"Phase II Trial J Clin Oncol"},{"issue":"1","key":"3440_CR112","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12871-022-01646-0","volume":"22","author":"X Wu","year":"2022","unstructured":"Wu X, Sun Q, He S et al (2022) Ropivacaine inhibits wound healing by suppressing the proliferation and migration of keratinocytes via the PI3K\/AKT\/mTOR Pathway. BMC Anesthesiol 22(1):106. https:\/\/doi.org\/10.1186\/s12871-022-01646-0","journal-title":"BMC Anesthesiol"},{"issue":"12","key":"3440_CR113","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1042\/CS20190772","volume":"134","author":"L Xenou","year":"2020","unstructured":"Xenou L, Papakonstanti EA (2020) p110delta PI3K as a therapeutic target of solid tumours. Clin Sci (lond) 134(12):1377\u20131397. https:\/\/doi.org\/10.1042\/CS20190772","journal-title":"Clin Sci (lond)"},{"issue":"7","key":"3440_CR114","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","volume":"21","author":"Q Yang","year":"2015","unstructured":"Yang Q, Modi P, Newcomb T, Queva C, Gandhi V (2015) Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res 21(7):1537\u20131542. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2034","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3440_CR115","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.annonc.2020.12.009","volume":"32","author":"HY Yhim","year":"2021","unstructured":"Yhim HY, Kim T, Kim SJ et al (2021) Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): an open-label phase I\/II trial. Ann Oncol 32(4):552\u2013559. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.009","journal-title":"Ann Oncol"},{"issue":"3","key":"3440_CR116","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.celrep.2017.06.054","volume":"20","author":"J Zhang","year":"2017","unstructured":"Zhang J, Gao X, Schmit F et al (2017) CRKL Mediates p110beta-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep 20(3):549\u2013557. https:\/\/doi.org\/10.1016\/j.celrep.2017.06.054","journal-title":"Cell Rep"},{"key":"3440_CR117","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jconrel.2019.07.039","volume":"309","author":"X Zhang","year":"2019","unstructured":"Zhang X, Shen L, Liu Q, Hou L, Huang L (2019) Inhibiting PI3 kinase-gamma in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors. J Control Release 309:173\u2013180. https:\/\/doi.org\/10.1016\/j.jconrel.2019.07.039","journal-title":"J Control Release"},{"key":"3440_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312813","author":"B Zhang","year":"2021","unstructured":"Zhang B, Luk C, Valadares J, Aronis C, Foukas LC (2021) Dominant Role of PI3K p110alpha over p110beta in Insulin and beta-Adrenergic Receptor Signalling. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222312813","journal-title":"Int J Mol Sci"},{"key":"3440_CR119","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13046-016-0356-5","volume":"35","author":"HF Zhao","year":"2016","unstructured":"Zhao HF, Wang J, Jiang HR, Chen ZP, To SS (2016) PI3K p110beta isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition. J Exp Clin Cancer Res 35:78. https:\/\/doi.org\/10.1186\/s13046-016-0356-5","journal-title":"J Exp Clin Cancer Res"},{"key":"3440_CR120","doi-asserted-by":"publisher","first-page":"14920","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Lwin T, Silva A et al (2017) Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun 8:14920. https:\/\/doi.org\/10.1038\/ncomms14920","journal-title":"Nat Commun"},{"issue":"7752","key":"3440_CR121","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-019-1082-x","volume":"568","author":"L Zhou","year":"2019","unstructured":"Zhou L, Chu C, Teng F et al (2019) Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2. Nature 568(7752):405\u2013409. https:\/\/doi.org\/10.1038\/s41586-019-1082-x","journal-title":"Nature"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-023-03440-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-023-03440-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-023-03440-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T04:19:42Z","timestamp":1677471582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-023-03440-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,11]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["3440"],"URL":"https:\/\/doi.org\/10.1007\/s00204-023-03440-4","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,11]]},"assertion":[{"value":"22 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}